Open House Drug Discount Agreements Diclofenac, ATC D11AX18
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Diclofenac, ATC D11AX18
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Open-house model does not guarantee any volume; revenue depends on patients using the discount agreement.
Strict document requirements (two paper originals or qualified electronic signature) can cause delays if not followed p...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Mar 2028
- Non-exclusive discount agreements for Diclofenac (ATC D11AX18) with AOK Bayern
- Open-house model: all eligible pharmaceutical companies can join without selection
Show full summary
This is an open-house model (not a traditional procurement) by AOK Bayern for non-exclusive discount agreements on Diclofenac (ATC D11AX18) under §130a Abs. 8 SGB V. Any eligible pharmaceutical company can conclude an identical, non-negotiable contract. Contracts run from April 1, 2026 to March 31, 2028, with enrollment possible at any time until February 3, 2028. No estimated value is provided.
Risks
Open-house model does not guarantee any volume; revenue depends on patients using the discount agreement.
Strict document requirements (two paper originals or qualified electronic signature) can cause delays if not followed p...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company
Administrative
- Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submit signed contract and annex listing covered medicines
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Drug Discount Agreements Diclofenac, ATC D11AX18
Non-exclusive discount agreements for Diclofenac (ATC D11AX18) with AOK Bayern. All pharmaceutical companies meeting eligibility can join. Contract duration: April 1, 2026 to March 31, 2028.
Location
Duration
Category
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Diclofenac, ATC D11AX18
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 15 Feb 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 108714-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Open-house model does not guarantee any volume; revenue depends on patients using the discount agreement.
Strict document requirements (two paper originals or qualified electronic signature) can cause delays if not followed p...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications